Anti-NMDA receptor encephalitis causes: Difference between revisions
Jump to navigation
Jump to search
(→Causes) |
(→Causes) |
||
Line 74: | Line 74: | ||
| Sensitivity 67%, specificity 95% for SCLC in LEMS | | Sensitivity 67%, specificity 95% for SCLC in LEMS | ||
|} | |} | ||
{|class="wikitable" | |||
|+ Partially characterized onconeural antibodies (antigen not characterized or positive predictive value for tumor unknown) | |||
|- | |||
! Antibodies | |||
! Antigens | |||
! Associated symptoms | |||
! Tumors | |||
|- | |||
| Anti-Tr (PCA-Tr) | |||
| DNER | |||
| Cerebellar degeneration | |||
| Hodgkin lymphoma, non-Hodgkin lymphoma | |||
|- | |||
| Anti-Zic4 | |||
| ZIC1-4 | |||
| Cerebellar degeneration | |||
| SCLC | |||
|- | |||
| PCA-2 | |||
| 280 kD | |||
| Encephalitis, Lambert–Eaton myasthenic syndrome, polyneuropathy | |||
| SCLC | |||
|- | |||
| ANNA-3 | |||
| 170 kD | |||
| Neuropathy, cerebellar degeneration, limbic encephalitis | |||
| SCLC | |||
|} | |||
SCLC: Small cell lung carcinoma; LEMS: Lambert–Eaton myasthenic syndrome (LEMS). | |||
==References== | ==References== |
Revision as of 00:36, 20 January 2023
Anti-NMDA receptor encephalitis Microchapters |
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Anti-NMDA receptor encephalitis causes On the Web |
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis causes |
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
Risk calculators and risk factors for Anti-NMDA receptor encephalitis causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; AE Dheeraj Makkar, M.D.[2]
Overview
Causes
Antibodies | Antigens | Associated symptoms | Tumors |
---|---|---|---|
Anti-Hu (ANNA-1) | HuD | Encephalomyelitis, limbic encephalitis, cerebellar degeneration, brain stem encephalitis, multi-segmental myelitis, sensory neuronopathy, sensory motor neuropathy, autonomic neuropathy | Lung cancer (85%), mostly SCLC, neuroblastoma, prostate carcinoma |
Anti-Yo (PCA-1) | CDR2, CDR62 | Paraneoplastic cerebellar degeneration | Ovarian, breast cancer |
Anti-CV2(CRMP5) | CRMP5 | Encephalomyelitis, polyneuropathy, optic neuritis, limbic encephalitis, choreatic syndromes, cerebellar degeneration | SCLC, thymoma |
Anti-Ta/Ma2 | MA-proteins | Limbic encephalitis, rhombencephalitis, male>>female | Testicular cancer |
Anti-Ri (ANNA-2) | NOVA-1 | Opsoclonus–myoclonus syndrome, rhombencephalitis, cerebellar degeneration, myelitis, jaw dystonia, laryngospasm | Breast, ovarian carcinoma, SCLC |
Anti-amphiphysin | Amphiphysin | Stiff-person syndrome, limbic encephalitis, rhombencephalitis, cerebellar degeneration, polyneuropathy | Breast cancer, SCLC |
Anti-recoverin | Recoverin | Retinopathy | SCLC |
Anti-SOX-1 (AGNA) | SOX-1 | Non-syndrome-specific | Sensitivity 67%, specificity 95% for SCLC in LEMS |
Antibodies | Antigens | Associated symptoms | Tumors |
---|---|---|---|
Anti-Tr (PCA-Tr) | DNER | Cerebellar degeneration | Hodgkin lymphoma, non-Hodgkin lymphoma |
Anti-Zic4 | ZIC1-4 | Cerebellar degeneration | SCLC |
PCA-2 | 280 kD | Encephalitis, Lambert–Eaton myasthenic syndrome, polyneuropathy | SCLC |
ANNA-3 | 170 kD | Neuropathy, cerebellar degeneration, limbic encephalitis | SCLC |
SCLC: Small cell lung carcinoma; LEMS: Lambert–Eaton myasthenic syndrome (LEMS).